<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30799464</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Print"><Volume>155</Volume><Issue>1</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>[C&#xe9;lulas T reguladoras en lupus eritematoso generalizado].</ArticleTitle><Pagination><StartPage>72</StartPage><EndPage>79</EndPage><MedlinePgn>72-79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.18004165</ELocationID><Abstract><AbstractText>El lupus eritematoso generalizado (LEG) es una enfermedad autoinmune cr&#xf3;nica caracterizada por la p&#xe9;rdida de la tolerancia a los ant&#xed;genos propios y la s&#xed;ntesis de diferentes autoanticuerpos con la formaci&#xf3;n y dep&#xf3;sito de complejos inmunes y el da&#xf1;o de m&#xfa;ltiples &#xf3;rganos. Las c&#xe9;lulas T reguladoras (Treg) desempe&#xf1;an un papel esencial en el mantenimiento de la tolerancia perif&#xe9;rica, controlan el estado de activaci&#xf3;n del sistema inmune y limitan las respuestas autoinmunes. El estudio del n&#xfa;mero y la funci&#xf3;n de las diferentes subpoblaciones de c&#xe9;lulas Treg en LEG ha sido objeto de una intensa investigaci&#xf3;n. Dependiendo del fenotipo de las c&#xe9;lulas Treg analizado se ha reportado que la frecuencia de estas c&#xe9;lulas en pacientes con LEG se encuentra disminuida, aumentada o sin alteraciones. Adem&#xe1;s, diferentes grupos han descrito que la funci&#xf3;n supresora de las c&#xe9;lulas Treg de los pacientes con LEG se encuentra reducida o no se ve afectada. En conjunto, lo datos reportados sugieren que las c&#xe9;lulas Treg desempe&#xf1;an un papel relevante en la patog&#xe9;nesis del LEG y que estos linfocitos pueden ser considerados blancos potenciales para el dise&#xf1;o de nuevas estrategias terap&#xe9;uticas para esta enfermedad.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2019 Secretar&#xcd;a de Salud.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Layseca-Espinosa</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departamento de Inmunolog&#xed;a, Facultad de Medicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsiv&#xe1;is-Urenda</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Inmunolog&#xed;a, Facultad de Medicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Don&#xed;z-Padilla</LastName><ForeName>Lesly</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Inmunolog&#xed;a, Facultad de Medicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portillo-Salazar</LastName><ForeName>Hayd&#xe9;e</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Departamento de Inmunolog&#xed;a, Facultad de Medicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Castro</LastName><ForeName>Berenice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departamento de Inmunolog&#xed;a, Facultad de Medicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitales-Noyola</LastName><ForeName>Marlen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Maestr&#xed;a en Endodoncia, Facultad de Estomatolog&#xed;a. Universidad Aut&#xf3;noma de San Luis Potos&#xed;, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Amaro</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Inmunolog&#xed;a, Facultad de Medicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Ciencias de la Salud y Biomedicina, San Luis Potos&#xed;, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a loss of tolerance to self-antigens and synthesis of different autoantibodies, with the formation and deposition of immune complexes and damage to multiple organs. T regulatory cells (Tregs) play a crucial role in maintaining peripheral tolerance, controlling the state of activation of the immune system and limiting autoimmune responses. The study of the number and function of the different Treg cell subpopulations in SLE has been the subject of intense research. Depending on the analyzed Treg cell phenotype, the frequency of these cells has been reported to be reduced, increased or unaltered in patients with SLE. In addition, different groups have described that Treg cells suppressive function is reduced or unaffected in patients with SLE. Taken together, the reported data suggest that Treg cells play a relevant role in the pathogenesis of SLE and that these lymphocytes can be considered potential targets for the design of new therapeutic strategies for this condition.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2019 Secretar&#xcd;a de Salud.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immune response regulation</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Treg cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30799464</ArticleId><ArticleId IdType="doi">10.24875/GMM.18004165</ArticleId><ArticleId IdType="pii">j155/1/72</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27762457</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0705</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology</Title><ISOAbbreviation>Ultrasound Obstet Gynecol</ISOAbbreviation></Journal><ArticleTitle>Longitudinal hemodynamics in acute phase of treatment with labetalol in hypertensive pregnant women to predict need for vasodilatory therapy.</ArticleTitle><Pagination><StartPage>85</StartPage><EndPage>94</EndPage><MedlinePgn>85-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/uog.17335</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Hypertensive pregnant women who do not respond to treatment with labetalol to control blood pressure (BP), but require vasodilatory therapy, progress rapidly to severe hypertension. This could be delayed by early recognition and individualized treatment. In this study, we sought to create prediction models from data at presentation and at 1 h and 24 h after commencement of treatment to identify patients who will not have a sustained response to labetalol and therefore need vasodilatory therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study population comprised 134 women presenting with hypertension at a UK hospital. Treatment with oral labetalol was administered when BP was &gt; 150/100 mmHg or &gt; 140/90 mmHg with systemic disease. BP and hemodynamic parameters were recorded at presentation and at 1 h and 24 h after commencement of treatment. Labetalol doses were titrated to maintain BP around 135/85 mmHg. Women with unresponsive BP, despite labetalol dose maximization (2400 mg/day), received additional vasodilatory therapy with nifedipine. Binary logistic and longitudinal (mixed-model) data analyses were performed to create prediction models anticipating the likelihood of hypertensive women needing vasodilatory therapy. The prediction models were created from data at presentation and at 1 h and 24 h after treatment, to assess the value of central hemodynamics relative to the predictive power of BP, heart rate and demographic variables at these intervals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-two percent of our cohort required additional vasodilatory therapy antenatally. These women had higher rates of severe hypertension and delivered smaller babies at earlier gestational ages. The unresponsive women were more likely to be of black ethnicity, had higher BP and peripheral vascular resistance (PVR), and lower heart rate and cardiac output (CO) at presentation. Those who needed vasodilatory therapy showed an initial decrease in BP and PVR, which rebounded at 24 h, whereas BP and PVR in those who responded to labetalol showed a sustained decrease at 1 h and 24 h. Stroke volume and CO did not decrease during the acute phase of treatment in either group. The best model for prediction of the need for vasodilators was provided at 24 h by combining ethnicity and longitudinal BP and heart rate changes. The model achieved a detection rate of 100% for a false-positive rate of 20% and an area under the receiver-operating characteristics curve of 0.97.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Maternal demographics and hemodynamic changes in the acute phase of labetalol monotherapy provide a powerful tool to identify hypertensive pregnant patients who are unlikely to have their BP controlled by this therapy and will consequently need additional vasodilatory therapy. Copyright &#xa9; 2016 ISUOG. Published by John Wiley &amp; Sons Ltd.</AbstractText><AbstractText Label="RESUMEN OBJETIVO" NlmCategory="UNASSIGNED">Las embarazadas hipertensas que no responden al tratamiento con labetalol para el control de la presi&#xf3;n arterial (PA), pero que requieren terapia vasodilatadora, evolucionan r&#xe1;pidamente hacia una hipertensi&#xf3;n severa. &#xc9;sta se puede retrasar mediante un diagn&#xf3;stico precoz y un tratamiento individual. En este estudio se ha tratado de crear modelos de predicci&#xf3;n a partir de datos al inicio del tratamiento y al cabo de 1 hora y de 24 horas despu&#xe9;s del mismo, para identificar a las pacientes que no mostrar&#xe1;n una respuesta constante al labetalol y que por lo tanto necesitar&#xe1;n terapia vasodilatadora. M&#xc9;TODOS: La poblaci&#xf3;n de estudio incluy&#xf3; 134 mujeres con hipertensi&#xf3;n en un hospital del Reino Unido. El tratamiento con labetalol por v&#xed;a oral se administr&#xf3; cuando la PA fue &gt;150/100 mm de Hg o &gt;140/90 mm de Hg con enfermedad multisist&#xe9;mica. Se registr&#xf3; la PA y los par&#xe1;metros hemodin&#xe1;micos tanto al inicio como al cabo de 1 h y de 24 h despu&#xe9;s del inicio del tratamiento. Las dosis de Labetalol se ajustaron para mantener la PA en torno a los 135/85 mm de Hg. Las mujeres cuya PA no produjo respuesta, a pesar de haberles administrado la dosis m&#xe1;xima de labetalol (2400 mg/d&#xed;a), recibieron terapia vasodilatadora adicional con nifedipino. Se realizaron an&#xe1;lisis de datos mediante log&#xed;stica binaria y longitudinal (modelo mixto), para crear modelos de predicci&#xf3;n con los que pronosticar la probabilidad de la necesidad de terapia vasodilatadora en mujeres hipertensas. Los modelos de predicci&#xf3;n se crearon a partir de datos al inicio y al cabo de 1 hora y 24 horas del tratamiento, para evaluar el valor de los par&#xe1;metros hemodin&#xe1;micos principales con respecto a la capacidad predictiva de la PA, la frecuencia card&#xed;aca y las variables demogr&#xe1;ficas en estos intervalos.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">El 22 % de la cohorte necesit&#xf3; terapia vasodilatadora adicional antes del parto. Estas mujeres tuvieron tasas m&#xe1;s altas de hipertensi&#xf3;n grave y neonatos m&#xe1;s peque&#xf1;os en edades gestacionales m&#xe1;s tempranas. Las mujeres que no respondieron al tratamiento fueron con m&#xe1;s frecuencia de raza negra, tuvieron la PA y la resistencia vascular perif&#xe9;rica (RVP) m&#xe1;s alta, y la frecuencia card&#xed;aca y el gasto card&#xed;aco (GC) m&#xe1;s bajos al inicio del tratamiento. Aquellas que necesitaron terapia vasodilatadora mostraron un descenso inicial de la PA y la RVP, que se recuper&#xf3; al cabo de 24 h, mientras que la PA y la RVP en las que respondieron al labetalol mostraron una disminuci&#xf3;n constante al cabo de 1 h y de 24 h. El volumen sist&#xf3;lico y el GC no disminuyeron durante la fase aguda del tratamiento en ninguno de los grupos. El mejor modelo para la predicci&#xf3;n de la necesidad de vasodilatadores se obtuvo a las 24 h mediante la combinaci&#xf3;n de la etnia con los cambios longitudinales de la PA y la frecuencia card&#xed;aca. El modelo alcanz&#xf3; una tasa de detecci&#xf3;n del 100% para una tasa de falsos positivos del 20% y un &#xe1;rea bajo la curva de caracter&#xed;sticas operativas del receptor de 0,97. CONCLUSI&#xd3;N: Los datos demogr&#xe1;ficos maternos y los cambios hemodin&#xe1;micos en la fase aguda de la monoterapia con labetalol constituyen una herramienta poderosa para identificar a las pacientes embarazadas hipertensas con pocas probabilidades de que se les pueda controlar su PA mediante esta terapia y que por lo tanto necesitar&#xe1;n terapia vasodilatadora adicional. : &#x3001;(blood pressure,BP),&#x3002;&#x3002;,1 h24 h,&#x3002; : 134&#x3002;BP&gt;150/100 mmHgBP&gt;140/90 mmHg&#x3002;1 h24 hBP&#x3002;,BP135/85 mmHg&#x3002;BP,()&#x3002;logistic(),&#x3002;1 h24 h,,BP&#x3001;&#x3002; : 22%&#x3002;&#x3002;,BP(peripheral vascular resistance,PVR),(cardiac output,CO)&#x3002;BPPVR,24 h,1 h24 hBPPVR&#x3002;CO&#x3002;24hBP&#x3002;100%,20%,0.97&#x3002; : ,BP&#x3002;.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 ISUOG. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stott</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Antenatal Hypertension Clinic, Division of Women's Health, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolten</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Antenatal Hypertension Clinic, Division of Women's Health, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paraschiv</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Antenatal Hypertension Clinic, Division of Women's Health, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papastefanou</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Leto Maternity Unit, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chambers</LastName><ForeName>J B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Cardiothoracic Centre, Guy's and St Thomas' Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kametas</LastName><ForeName>N A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Antenatal Hypertension Clinic, Division of Women's Health, King's College Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harris Birthright Research Centre for Fetal Medicine, Division of Women's Health, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ultrasound Obstet Gynecol</MedlineTA><NlmUniqueID>9108340</NlmUniqueID><ISSNLinking>0960-7692</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>R5H8897N95</RegistryNumber><NameOfSubstance UI="D007741">Labetalol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007230" MajorTopicYN="N">Infant, Low Birth Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007741" MajorTopicYN="N">Labetalol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014655" MajorTopicYN="N">Vascular Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">maternal medicine</Keyword><Keyword MajorTopicYN="N">pre-eclampsia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27762457</ArticleId><ArticleId IdType="doi">10.1002/uog.17335</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>